Handelsavisen
prelaunch
Companies ›Consumer Cyclicals ›471820.KQ
47
471820.KQ — KOSDAQ Miscellaneous Specialty Retailers

Cellromax Science Co Ltd

$4 645,00
Open in Charts → Attach watcher ⌖
— —
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
51,9B KRW
P/E
18,3x
EV / Rev
2,4x
Div yield
3,77 %
Op margin
34,2 %
ROE
6,8 %
Net margin
42,5 %
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Cellromax Science Co Ltd operates in the retail sector, specializing in miscellaneous specialty retail, and generates revenue primarily through the sale of goods to consumers.

Business. Cellromax Science Co Ltd (471820.KQ) is a miscellaneous specialty retailer operating within the consumer cyclicals sector. The company is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorConsumer Cyclicals
Business sectorRetailers
IndustryMiscellaneous Specialty Retailers
ActivityRetailers
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation→
18,3x
P/E
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
6,8 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 471820.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary · THIS SECTOR+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 471820.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Cellromax Science Co Ltd (471820.KQ) is a miscellaneous specialty retailer operating within the consumer cyclicals sector. The company is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorConsumer Cyclicals
    Business sectorRetailers
    IndustryMiscellaneous Specialty Retailers
    ActivityRetailers
    AI synthesis
    GENERATED

    Cellromax Science Co Ltd maintains a strong liquidity position, with a current ratio of 4.89 and cash and equivalents amounting to KRW 1,581,325,500. The company's debt-to-equity ratio is 0.01, indicating a low reliance on debt financing and a conservative capital structure. The price-to-book ratio of 1.68 suggests that the market values the company slightly above its book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible assets.

    In terms of profitability, the company's return on equity (ROE) is 6.82%, and its return on assets (ROA) is 6.1%, both of which are strong indicators of efficient use of equity and assets. The operating margin, calculated as operating income divided by revenue, is 34.27%, which is a high margin for a retail company and suggests effective cost management.

    The company's revenue is not segmented by product or geographic region in the provided data, so it is not possible to determine the concentration of revenue across different segments or regions. However, the company's overall revenue of KRW 5,187,565,910 indicates a substantial retail operation.

    The company's growth trajectory is not explicitly detailed in the provided data, but the strong operating and net income figures suggest a stable and profitable business model. The capital expenditure of KRW -131,723,520 indicates that the company is not currently investing heavily in new assets, which may suggest a focus on maintaining existing operations rather than expansion.

    The risk assessment indicates that the company has low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's low debt-to-equity ratio and high current ratio further support the low liquidity risk assessment. There is no indication of significant dilution potential, as the number of shares outstanding is the same for both basic and diluted shares.

    There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The company appears to be operating in a stable environment with no immediate financial or operational risks identified.

    Key takeaways
    • Cellromax Science Co Ltd has a strong liquidity position with a current ratio of 4.89 and a low debt-to-equity ratio of 0.01.
    • The company's profitability is robust, with a return on equity of 6.82% and a return on assets of 6.1%.
    • The company's capital structure is conservative, with a low reliance on debt financing.
    • The company's growth trajectory is not explicitly detailed, but the strong operating and net income figures suggest a stable and profitable business model.
    • The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 2

    Debt-to-equity ratio of 0.01 is well below the 0.31 cohort median, reflecting a conservative and low-leverage capital structure.

    Low dilution, liquidity, and credit risk flags suggest a stable operational environment with minimal immediate financial threats.

    BEAR CASE · 2

    Net income CAGR of -7.1% over four years reveals a persistent long-term downward trend in earnings.

    Cash conversion ratio of 1.15 trails the 1.22 cohort median, suggesting slightly weaker efficiency in converting profits to cash.

    In focus — financials by report

    Valuation FY

    Market price
    $4 645,00
    Market cap
    $54.21B
    Enterprise valueⓘ
    $53.08B
    P/Eⓘ
    18.3x
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    2.4x
    EV / Op incomeⓘ
    18.9x
    EV / OCFⓘ
    20.9x
    P / Bⓘ
    1.7x
    P / Tangible bookⓘ
    1.7x
    Tangible book
    $32.32B
    Net cashⓘ
    $1.12B
    Current ratioⓘ
    4.9
    Debt / equityⓘ
    0.0
    ROAⓘ
    6.1%
    ROEⓘ
    6.8%
    Cash conversionⓘ
    115.0%
    CapEx / revenueⓘ
    -2.5%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin34,2 %Best in class
    Net Margin42,5 %Best in class
    ROE6,8 %Above median
    Capex / Rev-2,5 %Below median
    D/E0,01Above P75
    Cash Conv1,15Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Cellromax Science Co Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    471820.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage